尿血管紧张素原在肾脏病中的应用研究进展  

Research advances of applications of urinary angiotensinogen for kidney disease

作　　者：白玉环 廖晓辉[1] Bai Yu-huan;Liao Xiao-hui(Department of Nephrology,Second Affiliated Hospital,Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院肾内科,400010

出　　处：《临床肾脏病杂志》2021年第1期64-68,共5页Journal Of Clinical Nephrology

基　　金：国家自然基金面上项目(81873604);国家临床重点专科建设项目(卫生办医政[2012]649);重庆市科委科技局技术创新与应用发展面上项目(cstc2019jscx-msxmX0127);重庆市留学人员创新创业计划(cx2018038)。

摘　　要：急性肾损伤(acute kidney injury,AKI)和慢性肾脏病(chronic kidney disease,CKD)的患病率在全球范围内持续上升。多项研究结果表明,在AKI和CKD发病机制中,肾素-血管紧张素系统(renin-angiotensin system,RAS)的持续激活,特别是血管紧张素Ⅱ的产生,与促炎、促纤维化途径的激活有关,由此成为AKI和CKD发展重要的驱动因素。有研究显示,相比检测循环中的RAS的活性,尿液血管紧张素原更能反映肾内RAS活性。综合近几年的研究结果,尿液血管紧张素原可能作为一种生物标志物在预测AKI和CKD的发生发展中发挥重要作用。The prevalence of acute kidney injury(AKI)and chronic kidney disease(CKD)continues spiking globally.Many studies have attributed the pathogenesis of AKI/CKD to a continuous activation of renin-angiotensin system(RAS).Particularly the production of angiotensinⅡ(AngⅡ)is correlated with activating pro-inflammatory and pro-fibrotic pathways so that it has become an important driving factor for the development of AKI/CKD.It was reported that urinary angiotensinogen(UAGT),as a biomarker,could reflect the activity of RAS in kidney better than the detection of RAS activity in circulation.Based upon recent researches,UAGT played an important role in the occurrence and development of AKI/CKD.

关 键 词：血管紧张素原 急性肾损伤 慢性肾脏病 生物标志物 

分 类 号：R692[医药卫生—泌尿科学]